Matfors, Sweden / Vienna, Austria — May 26, 2026
NorthX Biologics and enGenes Biotech have partnered to offer an integrated development and manufacturing pathway for recombinant protein programs in E. coli. The partnership addresses the disconnect between initial expression system development and GMP manufacturing, which saves early-stage programs three to six months in development time. The pathway helps biopharma developers reach clinical milestones faster, reducing scale-up risk and improving process predictability.
E. coli-based recombinant protein production is a cornerstone of the biopharmaceutical industry. Yet the transition from development to clinical-phase manufacturing is often handled across multiple providers, creating delays during process transfer and scale-up. The partnership integrates strain engineering, expression optimization, process development, and manufacturing into a single workflow.
Janet Hoogstraate, CEO, NorthX Biologics, says: “The biotech companies we work with are under real pressure. Less capital, faster timelines, higher expectations from investors. Still, programs arrive at GMP with expression systems that were never built to scale, and fixing that can take months. This partnership exists to change that by making manufacturability part of the conversation from the start. In the current environment, that kind of predictability determines whether a program moves forward at all.”
The partnership combines enGenes’ proprietary enGenes-eXpress™ platform, which delivers decision-grade expression data within weeks, with NorthX Biologics’ capabilities in process development, analytics, scale-up, and GMP manufacturing. The result is a continuous workflow from early expression screening to GMP-ready material, with process parameters aligned to GMP requirements from the first expression run.
Jürgen Mairhofer, CEO, enGenes Biotech, says: “The timing of this partnership reflects where the market is heading. Biosimilar pipelines are expanding, cost pressures are intensifying, and customers are looking for manufacturing solutions that are both technically differentiated and GMP-credible from day one. enGenes has built a next-generation E. coli platform with key enabling technologies that improve the cost-efficiency and speed of biologics production. NorthX Biologics has the GMP infrastructure and regulatory track record to bring that to patients. Together, we close a gap that neither of us could close alone.”
Under the partnership terms, enGenes performs high-throughput expression optimization, including host/vector screening, soluble expression enhancement, extracellular secretion strategies, and antibiotic marker-free production. The resulting expression system and full technical data package are transferred directly into NorthX Biologics’ pre-validated development and GMP manufacturing workflow. This creates a continuous pathway from genetic construct to clinical-grade material.
As cost pressure and pipeline complexity push biopharma toward microbial expression systems, the partnership addresses a long-standing gap that historically made programs slower and more risk-prone. The pathway enables decision-grade expression data within weeks and earlier Go/No-Go decisions. The companies now offer the pathway to both new and existing customers.
About NorthX Biologics: NorthX Biologics is a leading contract development and manufacturing organization (CDMO) and Sweden’s national innovation hub for advanced biologics, enabling next-generation therapies beyond traditional manufacturing. With over 30 years of GMP experience, NorthX Biologics offers end-to-end services including process development, recombinant proteins, vaccines, viral vectors, cell therapies, and aseptic fill & finish. With its headquarters in Matfors, Sweden, and a facility in Stockholm, NorthX Biologics serves customers worldwide.
About enGenes Biotech: enGenes Biotech is a microbial expression technology company specialising in high-performance recombinant protein, peptide, and plasmid DNA production in E. coli. Founded in 2014 and headquartered in Vienna, Austria, the company has built a portfolio of proprietary platforms that consistently deliver titers, solubility, and secretion performance beyond the reach of conventional E. coli systems. Recent peer-reviewed work demonstrated secreted VHH titers of 17 g/L in E. coli, the highest reported in any microbial host. enGenes combines this technology base with end-to-end bioprocess development expertise, from molecular biology and strain engineering through upstream and downstream process design, supporting pharmaceutical, diagnostic, and industrial biotech clients worldwide in reducing production costs and accelerating time to market.
Media Contacts:
Janet Hoogstraate, CEO, NorthX Biologics
[email protected]
www.nxbio.com
Juergen Mairhofer, CEO, enGenes Biotech
[email protected]
www.engenes.cc
Stay updated with the latest NorthX Biologics news, events and insights by subscribing to our newsletter.
